Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9NT62
UPID:
ATG3_HUMAN
Alternative names:
Autophagy-related protein 3; Protein PC3-96
Alternative UPACC:
Q9NT62; Q6PKC5; Q9H6L9
Background:
Ubiquitin-like-conjugating enzyme ATG3, also known as Autophagy-related protein 3 or Protein PC3-96, plays a pivotal role in autophagy, mitochondrial homeostasis, and the cytoplasm to vacuole transport (Cvt). It is essential for the E2-like covalent binding of phosphatidylethanolamine to ATG8-like proteins, facilitating their membrane association, which is crucial for autophagy and Cvt. ATG3 also acts as an autocatalytic E2-like enzyme in the conjugation of ATG12, affecting mitochondrial homeostasis.
Therapeutic significance:
Understanding the role of Ubiquitin-like-conjugating enzyme ATG3 could open doors to potential therapeutic strategies.